Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global primary hyperoxaluria treatment market size reached a value of about USD 18.91 million in 2023 and is expected to grow at a CAGR of 3.7% during the forecast period of 2024-2032. With the growing awareness of rare disease and genetic engineering advancement, the market is expected to reach a value of about USD 26.16 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Primary hyperoxaluria (PH) is a rare genetic disease caused by glyoxylate metabolism deficiencies. The PH is autosomal recessive and is classified into three types based on the responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). The kidney is the primary site of oxalate deposition, which in many cases leads to end-stage renal disease.
End stage renal disease (ESRD) is a life-threatening condition that prevents the kidneys from effectively filtering fluids and waste products from the body.
Kidney stones in primary hyperoxaluria type 1 typically appear between childhood and early adulthood, and ESRD can develop at any age. The symptoms of primary hyperoxaluria type 2 are similar to those of type 1, but ESRD develops later in life. Primary hyperoxaluria type 3 patients frequently develop kidney stones in childhood, but few cases of this type have been described, so additional signs and symptoms are unknown.
Recurrent kidney stones, hematuria, and urinary tract infections (UTIs) are possible signs and symptoms. If left untreated, PH-I can progress to end-stage renal disease, which can be fatal. The disease is characterised phenotypically by the recurrent formation of kidney stones and nephrocalcinosis, which results in the gradual decline of kidney function. When renal function deteriorates, excess oxalate cannot be eliminated through the urine, and calcium oxalate crystals precipitate in various tissues, resulting in systemic oxalosis, a devastating multiorgan disease.
Changes (mutations) in the AGXT gene cause PH type I. Mutations in the GRHPR gene cause PH type II. Mutations in the HOGA1 gene cause PH type III. Genes encode instructions for the production of proteins, which are essential for many bodily functions. When a gene is mutated, the protein product may be faulty, inefficient, or absent. Depending on the functions of the specific protein, this can have an impact on many organ systems in the body.
According to the market research report, the primary hyperoxaluria treatment market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
Market Breakup by Diagnosis Method
Market Breakup by Treatment Method
Market Breakup by Treatment Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Males and females are equally affected by PH. These disorder’s exact incidence and prevalence are unknown. Because some cases go undiagnosed or are misdiagnosed, it is difficult to determine the true prevalence of these conditions in the general population. Young patients with recurring kidney stone formation may benefit from molecular genetic testing. However, some patients with common PH symptoms are not found to have the known genetic mutations linked to PH, implying that the true number of people with PH is likely to be underestimated. The most common form is PH type I.
According to one estimate, the prevalence of PH type I in the general population is 1-3 cases per 1,000,000 people, with fewer than 1,000 people affected in the United States, and the incidence is 1 case per 120,000 live births per year in Europe. PH is estimated to be 2.5 times more common in European Americans than in African Americans.
The population growing awareness of rare and genetic disorders is expected to drive the demand for primary hyperoxaluria treatment. During the forecast period, technological advancements in the field of genetic engineering will drive the demand for global primary hyperoxaluria treatment market.
The number of leading pharmaceutical companies with products in clinical trials for the treatment of primary hyperoxaluria will drive the market growth. In the coming decade, demand for primary hyperoxaluria treatment will rise due to an increase in diagnosis and treatment seeking. Global primary hyperoxaluria treatment market growth is hampered by a small patient population available for clinical trials.
Treatment is determined by the type, symptoms, and severity of hyperoxaluria, and by how well the patient responds to the treatment.
Treatment may necessitate the collaborative efforts of a team of specialists. Pediatricians, surgeons, specialists who assess and treat kidney problems (nephrologists), specialists who assess and treat liver problems (hepatologists), specialists who assess and treat urinary tract problems (urologists), dieticians, and other healthcare professionals may need to plan an affected child's treatment systematically and comprehensively. Genetic counselling is advised to assist families in understanding the genetics and natural history of PH, and to provide psychosocial support.
Lumasiran (Oxlumo) is a medication that reduces oxalate production in children and adults with primary hyperoxaluria. In some people with primary hyperoxaluria, prescription doses of vitamin B-6 can help reduce oxalate in the urine. Phosphate and citrate oral preparations aid in the prevention of calcium oxalate crystal formation. Depending on the other abnormalities in the urine, other medications, such as thiazide diuretics, may be considered.
The report gives an in-depth analysis of the key players involved in the global primary hyperoxaluria treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Diagnosis Method |
|
Breakup by Treatment Method |
|
Breakup by Treatment Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 18.91 million in 2023, driven by the growing awareness of rare disease and genetic engineering advancement.
The market is expected to rise at a CAGR of 3.7% during the forecast period of 2024-2032 to attain a value of USD 26.16 million by 2032.
The increased awareness of rare diseases and advancement in the genetic engineering is a critical factor driving the market growth.
Alnylam Pharmaceuticals, Tecoland Corporation, Zhejiang Tianxin Pharmaceuticals Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, Genentech, OxThera, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals among others are the leading companies in the market.
Small population available for the clinical trials will restrain the growth of the market.
Primary hyperroxaluria has no known cure. The goal is to protect the kidneys by preventing the formation of kidney stones and the formation and deposit of calcium oxalate in other body tissues.
Lumasiran (Oxlumo) is a medication that reduces oxalate production in children and adults with primary hyperoxaluria. In some people with primary hyperoxaluria, prescription doses of vitamin B-6 can help reduce oxalate in the urine.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124
Share